192 related articles for article (PubMed ID: 18000940)
21. The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.
Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Chandrasekhar J; Horvath RF; Ge P; Kershaw MT; Krause JE; Kehne J; Hoffman D; Doller D; Hodgetts KJ
Bioorg Med Chem Lett; 2008 Feb; 18(3):891-6. PubMed ID: 18180159
[TBL] [Abstract][Full Text] [Related]
22. Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor.
Aso K; Kobayashi K; Mochizuki M; Kanzaki N; Sako Y; Yano T
Bioorg Med Chem Lett; 2011 Apr; 21(8):2365-71. PubMed ID: 21414781
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
Gilligan PJ; Clarke T; He L; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy JF; Ward K; Zeller K; Wong H; Bai S; Saye J; Grossman S; Zaczek R; Arneric SP; Hartig P; Robertson D; Trainor G
J Med Chem; 2009 May; 52(9):3084-92. PubMed ID: 19361209
[TBL] [Abstract][Full Text] [Related]
24. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
[TBL] [Abstract][Full Text] [Related]
25. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G
J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210
[TBL] [Abstract][Full Text] [Related]
26. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.
Yamada Y; Mizutani K; Mizusawa Y; Hantani Y; Tanaka M; Tanaka Y; Tomimoto M; Sugawara M; Imai N; Yamada H; Okajima N; Haruta J
J Med Chem; 2004 Feb; 47(5):1075-8. PubMed ID: 14971886
[TBL] [Abstract][Full Text] [Related]
27. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.
Chen C; Dagnino R; De Souza EB; Grigoriadis DE; Huang CQ; Kim KI; Liu Z; Moran T; Webb TR; Whitten JP; Xie YF; McCarthy JR
J Med Chem; 1996 Oct; 39(22):4358-60. PubMed ID: 8893829
[No Abstract] [Full Text] [Related]
29. CRH-sub-1 receptor antagonists for the treatment of depression and anxiety.
Ising M; Holsboer F
Exp Clin Psychopharmacol; 2007 Dec; 15(6):519-28. PubMed ID: 18179304
[TBL] [Abstract][Full Text] [Related]
30. Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.
Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Nemeth GA; Arvanitis A; Cheeseman RS; Chorvat RJ; Ciganek E; Christos TE; Gilligan PJ; Krenitsky P; Scholfield E; Strucely P
J Med Chem; 1999 Mar; 42(5):819-32. PubMed ID: 10072680
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL
J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R).
Vrudhula VM; Dasgupta B; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Macor JE; Dubowchik GM
Bioorg Med Chem Lett; 2010 Mar; 20(6):1905-9. PubMed ID: 20185312
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
Hodgson RA; Higgins GA; Guthrie DH; Lu SX; Pond AJ; Mullins DE; Guzzi MF; Parker EM; Varty GB
Pharmacol Biochem Behav; 2007 Mar; 86(3):431-40. PubMed ID: 17291571
[TBL] [Abstract][Full Text] [Related]
35. Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.
Arvanitis AG; Gilligan PJ; Chorvat RJ; Cheeseman RS; Christos TE; Bakthavatchalam R; Beck JP; Cocuzza AJ; Hobbs FW; Wilde RG; Arnold C; Chidester D; Curry M; He L; Hollis A; Klaczkiewicz J; Krenitsky PJ; Rescinito JP; Scholfield E; Culp S; De Souza EB; Fitzgerald L; Grigoriadis D; Tam SW; Shen HL
J Med Chem; 1999 Mar; 42(5):805-18. PubMed ID: 10072679
[TBL] [Abstract][Full Text] [Related]
36. An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes.
Han X; Civiello R; Pin SS; Burris K; Balanda LA; Knipe J; Ren S; Fiedler T; Browman KE; Macci R; Taber MT; Zhang J; Dubowchik GM
Bioorg Med Chem Lett; 2007 Apr; 17(7):2026-30. PubMed ID: 17258456
[TBL] [Abstract][Full Text] [Related]
37. Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist.
Miller DC; Klute W; Calabrese A; Brown AD
Bioorg Med Chem Lett; 2009 Nov; 19(21):6144-7. PubMed ID: 19782566
[TBL] [Abstract][Full Text] [Related]
38. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
[TBL] [Abstract][Full Text] [Related]
39. Novel substituted tetrahydrotriazaacenaphthylene derivatives as potent CRF1 receptor antagonists.
Gentile G; Di Fabio R; Pavone F; Sabbatini FM; St-Denis Y; Zampori MG; Vitulli G; Worby A
Bioorg Med Chem Lett; 2007 Sep; 17(18):5218-21. PubMed ID: 17629700
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.
Webb TR; Moran T; Huang CQ; McCarthy JR; Grigoriadis DE; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3869-73. PubMed ID: 15225687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
